Navigation Links
Update: 50 percent of patients in Cedars-Sinai brain cancer study alive after 5 years
Date:11/23/2013

mors with all six, and 100 percent had tumors with at least four antigens associated with cancer stem cells cancer-originating cells that appear to enable tumors to resist radiation and chemotherapy and even regenerate after treatment.

"Our findings suggest that targeting antigens that are highly expressed by cancer stem cells may be a viable strategy for treating patients who have glioblastomas. Long-term remission of disease in this group of patients was correlated with the expression of cancer stem cell tumor-associated antigens," said Surasak Phuphanich, MD, director of the Neuro-Oncology Program at the Cochran Brain Tumor Center and professor of neurology with Cedars-Sinai's Department of Neurosurgery and Department of Neurology.

Based on results of the Phase I study, the ICT-107 vaccine entered a Phase II multicenter, randomized, placebo-controlled trial in 2011.

The vaccine is based on dendritic cells, the immune system's most powerful antigen-presenting cells those responsible for helping the immune system recognize invaders. They are derived from white blood cells taken from each participating patient in a routine blood draw. In the laboratory, the cells are cultured with synthetic peptides of the six antigens essentially training the dendritic cells to recognize the tumor antigens as targets. When the "new" dendritic cells in the vaccine are injected under the patient's skin, they are intended to seek and destroy lingering tumor cells. Vaccine is administered three times at two-week intervals after standard radiation and chemotherapy.

Phuphanich is first author of an abstract presented at the scientific meetings' poster session from 5 to 7 p.m. PST Nov. 23.

ICT-107 is a product of the biotechnology company ImmunoCellular Therapeutics, Ltd. Cedars-Sinai owns equity in the company, and certain rights in the dendritic cell vaccine technology and corresponding intellectual property have been exclusively licensed
'/>"/>

Contact: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. HRT Update: Therapy May Reduce Fractures, Boost Some Risks
2. Transvaginal Mesh Lawsuit Update: New Study Concerning Use of Vaginal Mesh in Prolapse Procedures, Bernstein Liebhard LLP Reports
3. Cell Phone Radiation Lawsuit Update: ICEMS Position Paper Supports Italian Supreme Court Ruling on Cell Phones and Brain Tumors, Bernstein Liebhard LLP Reports
4. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
5. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
6. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
7. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
8. Research update: Chemists find help from nature in fighting cancer
9. Yasmin Blood-Clotting Lawsuits Update: Resource4thePeople Providing Legal Assistance as Concerns Rise Over Health Risks
10. Tylenol Liver Failure Allegation Lawsuits Update: Resource4thePeople Reports Hearing to Consolidate Federal Cases Is Scheduled
11. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... Royal River Natural ... study that followed men and women for 19 years and found that, among those ... not take multivitamins. , The report is part of the September 2015 issue of ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... D.O., has joined its medical management team as an Associate Medical Director. ... sizes and types in the U.S. and abroad. , Dr. Nelson has ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Two of Washington ... cultural relations through food and dining. , Recently named “the next big thing” ... Diotaiuti are known for telling the whole story behind food and reclaiming culinary traditions ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, tax, ... named a “Best of the Best” firm in the U.S., as well as being ... of the Best” in the U.S., selected exclusively on performance in specific areas of ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Kit is now available. With the Connectivity Kit, EasySampler data is ... jacketed lab reactor control experiment, on a touchscreen platform. , EasySampler fully ...
Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... Northeast, and boys are at higher risk than girls, study ... sweeping government study of childhood cancers has found numerous differences ... and where he or she lives in the United States. ... cancers, the researchers found, and youngsters in the Northeast were ...
... June 2 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) ... its lead anticancer agent Cloretazine(R) (VNP40101M) in,combination with cytarabine ... had been presented at the 44th Annual Meeting of,the ... The Phase III trial started in March 2005 ...
... (ASCO) ... Annual Meeting -, IRVINE, Calif., June 2 ... an analysis from the,Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The results,suggest ... reduction in the risk of death in newly diagnosed,patients with metastatic osteosarcoma, ...
... Marketing and, Communications Professionals for Inspiring Tales of Patient and ... ... EL SEGUNDO, Calif., June 2 DaVita Inc., a leading,provider ... failure (CKD), today announced that the company,s internal,publication, DaVita Magazine: Stories ...
... BETHESDA, Md., June 2 /Xinhua-PRNewswire/ -- Chindex ... Western healthcare,services and products in the People,s ... division, United Family Healthcare (UFH), responded to,the ... personnel,and other in- kind donations., Roberta ...
... the overall rate of high school baseball-related injuries has ... injuries that occur has increased, according to a new ... Research and Policy (CIRP) of The Research Institute at ... estimated 132,000 high school baseball-related injuries occurred with an ...
Cached Medicine News:Health News:U.S. Childhood Cancers Vary by Sex, Region 2Health News:U.S. Childhood Cancers Vary by Sex, Region 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 2Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 3Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 5Health News:DaVita Magazine Takes Home Two Prestigious Hermes Creative Awards 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 3Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 4Health News:Injuries to high school baseball players becoming more serious 2
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
(Date:8/31/2015)...  DICOM Grid,  the #1 medical image exchange ... as a semifinalist for a Minnie award for ... are sponsored by Auntminnie.com, a comprehensive community website ... imaging industry.  Since 1999, the "Minnies" have provided ... contributions of their peers. Nominations are made by ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... The 45° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
Medicine Products: